Alteogen's SC technology value grows as Enhertu gets early breast cancer approval in Europe?
Predicted impact: Low
Enhertu approval and SC platform research already widely reported.
Alteogen알테오젠
196170 · KOSDAQ · ₩196170 · 알테오젠
₩218,500 ₩0 (0.00%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −41.27%
- Market cap
- ₩15T
- Enterprise value
- ₩15T
- P/E
- 78.8×
- P/B
- 28.4×
- Dividend yield
- 0.1%
- ROE
- 36.0%
- Net margin
- 76.0%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−50.1% from the high
₩194,663Today: ₩217,000 – ₩229,500₩437,799
Returns
- 1W−5.4%
- 1M−12.6%
- 3M−4.2%
- 6M−24.6%
- YTD−36.8%
- 1Y−41.3%
- Volume today
- 232,496
- 0.8× the 20-day average
- Traded today
- ₩52B
- Listed shares
- 69,655,133
- EPS (12 months)
- ₩2,772
- Earnings yield 1.3%
AI research · Update noteAlteogen Receives Request to Amend Merger Securities Registration StatementThe event is a procedural step in an unfinished merger process, and the data gives no new terms.Read the full report →
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 41 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: Partner drug approval in Europe is positive, though the filing is routine. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-12.4% over the last month; the price is below its 20-day average.
- News impactSome13 news items and filings in two weeks; 0 rated high impact, 2 medium.
Signals describe activity, not recommendations. Not financial advice.
Leveraged ETF flows
Estimated leveraged-ETF rebalance on Oct 27: buy ₩5.1B at the close (6.8% of 20-day average trading value)
On its 26 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 13.0% of trading value and pointed the same way 19 of 26 times.
- 2× KODEX KOSDAQ150 Leverage ₩4.2B
- 2× TIGER KOSDAQ150 Leverage ₩500M
- -1× KODEX KOSDAQ150 Futures Inverse ₩292M
- 2× RISE KOSDAQ150 Futures Leverage ₩87M
- 2× KIWOOM KOSDAQ150 Futures Leverage ₩22M
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
ETFs holding this
All ETFs →Held by 11 funds.
- KODEX KOSDAQ1506.0%
- KODEX KOSDAQ150 Leverage2×6.0%
- TIGER KOSDAQ1506.0%
- RISE KOSDAQ1506.0%
- TIGER KOSDAQ150 Leverage2×6.0%
- ACE KOSDAQ 1506.0%
- KIWOOM KOSDAQ1506.0%
- SOL KOSDAQ1506.0%
Estimated from the funds' index or underlying stock.
Futures and options
All stock futures →Futures (2026-11): 216,000
Basis −1.14% · implied rate −26.3%
Open interest 75,629 contracts
Options open interest: 2,781 calls, 2,376 puts (put/call 0.85)
Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.
Alteogen stock overview
Alteogen (알테오젠, KRX: 196170) is listed on KOSDAQ, in the Biotech & Pharma sector. The company is a Korean biotech that develops, manufactures and sells biopharmaceuticals, such as biobetters and novel biologics, based on its proprietary platform technologies, including Hybrozyme for converting intravenous drugs into subcutaneous formulations. Its shares closed at ₩218,500 on Oct 27, 2026, unchanged on the day, giving it a market value of ₩15T.
Key facts
- Market cap
- ₩15T
- Sector
- Biotech & Pharma
- Latest price change
- 0.00%
- As of
- Oct 27, 2026
- Main business
- The company is a Korean biotech that develops, manufactures and sells biopharmaceuticals, such as biobetters and novel biologics, based on its proprietary platform technologies, including Hybrozyme for converting intravenous drugs into subcutaneous formulations.
Quick answers about Alteogen
- What does Alteogen do?
- The company is a Korean biotech that develops, manufactures and sells biopharmaceuticals, such as biobetters and novel biologics, based on its proprietary platform technologies, including Hybrozyme for converting intravenous drugs into subcutaneous formulations. It licenses these platforms to global pharmaceutical companies, including MSD, AstraZeneca, GSK, Daiichi Sankyo and Sandoz, earning upfront, milestone and royalty income, and also develops biosimilars. Its key asset is ALT-B4 (berahyaluronidase alfa), and it launched a standalone hyaluronidase injection product in 2024 and has a biosimilar licensed in China and a product approved in Europe.
- What is the market cap of Alteogen?
- The market capitalisation of Alteogen was ₩15T at the close on Oct 27, 2026.
- Who are the largest shareholders of Alteogen?
- According to the latest official filings, the largest reported holders are Park Soon-jae (18.90%, as of Aug 13, 2026); Hyeong In-woo (5.11%, as of Nov 21, 2024); BlackRockFundAdvisors (5.03%, as of Aug 7, 2026).
- When is the next earnings report from Alteogen?
- Korean companies rarely announce results dates in advance. Based on when Alteogen filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Alteogen?
- Yes. The National Pension Service held 2.68% of Alteogen shares as of Dec 31, 2025.
Company profile
The company is a Korean biotech that develops, manufactures and sells biopharmaceuticals, such as biobetters and novel biologics, based on its proprietary platform technologies, including Hybrozyme for converting intravenous drugs into subcutaneous formulations. It licenses these platforms to global pharmaceutical companies, including MSD, AstraZeneca, GSK, Daiichi Sankyo and Sandoz, earning upfront, milestone and royalty income, and also develops biosimilars. Its key asset is ALT-B4 (berahyaluronidase alfa), and it launched a standalone hyaluronidase injection product in 2024 and has a biosimilar licensed in China and a product approved in Europe.
Written by AI from the company's latest annual report.
- Korean name
- 알테오젠
- Sector
- Biotech & Pharma
- CEO
- 전태연
- Founded
- May 2008
- Listed
- Dec 2014
- Listed shares
- 69,655,133
- Fiscal year ends
- Month 12
- Website
- www.alteogen.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
- SK Bioscience302440 · ₩2.5T₩31,750−0.78%
Recent news
Daedeok special district launches bio deep-tech open innovation with Alteogen; recruiting collaborative technologies
Predicted impact: Low
Open innovation with Daedeok zone repeats an earlier joint development report; small and exploratory.
Alteogen to seek next-generation drug candidates, pursues joint development with Daeduck Special Zone
Predicted impact: Low
Research collaboration to seek drug candidates is early-stage with no disclosed financial size.
Recent filings
See all- Securities registration statementOct 28, 2026
- Amended: Securities registration statementOct 19, 2026
- Securities Issuance Results (Voluntary Disclosure)Oct 14, 2026
- Securities Issuance Results (Voluntary Disclosure)Oct 14, 2026
- Securities registration statementOct 14, 2026
Titles in Korean until English translations are added.
Also known as: Alteogen / 알테오젠 / 196170 / KRX:196170
Source: KRX statistical information